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Background
A phase I clinical trial has recently assessed rAAV serotype
2 (rAAV2) as a vector for an HIV vaccine, however disap-
pointing immunogenicity was seen. Differences in the
ability of various serotypes to transduce dendritic cells
have been reported. Better defining the optimal serotype
for transduction of dendritic cells may increase its utility
as a T cell vaccine vector.
Methods
Six serotypes and three clones of rAAV expressing eGFP
were assessed for their ability to transduce human mono-
cytes and monocyte-derived dendritic cells (MoDCs).
Transduction was assessed by flow cytometry. In addition
a self-complimentary vector was compared with a conven-
tional vector. Site-directed mutagenesis of the rAAV6 cap-
sid was performed to further improve transduction
efficiency. The immunophenotype of transduced MoDCs
was assessed by flow cytometry. The ability of transduced
MoDCs to stimulate a CD8+ T cell clone was assessed.
Results
rAAV6 was the most efficient serotype transducing 4.3, 8.8
and 13.8 fold more MoDCs than rAAV2, rAAV5, and
rAAV1 respectively; a similar pattern was seen with mono-
cytes. Transduction of monocytes and MoDCs with rAAV6
led to similar rates of transgene expression by immature
MoDCs. There was no significant difference between self-
complimentary and conventional rAAV6 vectors at a range
of multiplicities of infection. Mutation of a surface tyro-
sine of the AAV6 capsid (Y731F) improved transduction
efficiency by a further 1.3 to 1.7 times. Transduction of
MoDCs did not alter their immunophenotype and they
were able to stimulate an antigen specific CD8+ T cell
clone.
Conclusion
This study extends the range of serotypes of rAAV previ-
ously examined and makes the novel finding that rAAV6
with an Y731F capsid mutation has the highest tropism
for MoDCs. In addition no advantage of a self-compli-
mentary genome was found, increasing the coding capac-
ity of the vector. These findings may improve the utility of
rAAV as a vaccine vector.
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